A UK randomized trial of 288 adults with noncystic fibrosis bronchiectasis found that hypertonic saline and carbocisteine did not significantly reduce exacerbations or improve quality of life versus standard care, suggesting limited clinical benefit and the need to reconsider routine mucoactive therapy use.
Can Mucoactive Therapy Change Bronchiectasis Outcomes?
Conexiant
November 10, 2025
